{"Clinical Trial ID": "NCT00688740", "Intervention": ["INTERVENTION 1:", "- TAC (Docetaxel)", "Docetaxel in combination with doxorubicin and cyclophosphamide", "INTERVENTION 2:", "FCC (5-fluorouracil)", "5-fluorouracil in combination with doxorubicin and cyclophosphamide"], "Eligibility": ["Incorporation criteria:", "A histologically proven breast cancer (invasive adenocarcinoma with at least one axillary lymph node showing signs of tumour among at least six resect lymph nodes).", "A definitive surgical treatment should be either mastectomy or breast conservation surgery with axillary dissection of lymph nodes for operational breast cancer.", "- Exclusion criteria:", "A prior systemic anticancer treatment for breast cancer (immunotherapy, hormone therapy, chemotherapy).", "An anterior anthracycline or taxoids (pallitaxel, docetaxel) for any malignancy."], "Results": ["Performance measures:", "Number of participants with disease-free survival events", "\u2022 Disease-free survival (SDF) is defined as a local, regional or metastatic relapse or the date of the second primary cancer or the death of any cause, whichever is the earlier.", "Time limit: up to 10 years of follow-up", "Results 1:", "Title of arm/group: TAC (Docetaxel)", "Description of the arm/group: docetaxel in combination with doxorubicin and cyclophosphamide", "Total number of participants analysed: 745", "Type of measurement: Number", "Unit of measure: Participants 287", "Results 2:", "- Arm/group title: FCC (5-fluorouracil)", "Description of the arm/group: 5-fluorouracil in combination with doxorubicin and cyclophosphamide", "Total number of participants analysed: 746", "Type of measurement: Number", "Unit of measure: Participants 333"], "Adverse Events": ["Undesirable Events 1:", "Total: 267/744 (35.89 per cent)", "Neutropenia 2/744 (0.27%)", "Anemia *1/744 (0.13%)", "*1/744 (0.13%)", "Thrombocytopenia *1/744 (0.13%)", "- Thrombocytopenic purpura *1/744 (0.13%)", "Atrial flute *1/744 (0.13%)", "Cardiac arrest *1/744 (0.13%)", "Myocardial ischemia *1/744 (0.13%)", "Arrhythmia *0/744 (0.00 %)", "Congestive heart failure *0/744 (0.00 %)", "Adverse Events 2:", "Total: 67/736 (9.10 per cent)", "Neutropenia *1/736 (0.14%)", "Anemia *0/736 (0.00 %)", "Leukopenia *0/736 (0.00 %)", "Thrombocytopenia *0/736 (0.00 %)", "- Thrombocytopenic purpura *0/736 (0.00 %)", "*0/736 (0.00 %)", "Cardiac arrest *0/736 (0.00 %)", "Myocardial ischemia *0/736 (0.00 %)", "Arrhythmia *2/736 (0.27%)", "Congestive heart failure *1/736 (0.14%)"]}